Use of TNFAlpha Inhibitor for Treatment of Psoriasis

• US 20150071938A1
• Filed: 10/09/2014
• Published: 03/12/2015
• Est. Priority Date: 04/09/2004
• Status: Active Grant

• Current Assignee: AbbVie Biotechnology Ltd. (Puerto Rico) (Abbvie Incorporated)
• Original Assignee: AbbVie Biotechnology Ltd. (Puerto Rico) (Abbvie Incorporated)
• Inventors: Hoffman, Rebecca S., Weinberg, Mark, Taylor, Lori K., Chartash, Elliot K., Yan, Philip, Granneman, George R.
• Granted Patent: US 8,986,693 B1
• Time in Patent Office: Days
• US Class Current: 424/142.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/70 Multivalent vaccine
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 49/0004 Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C07K 16/241 Tumor Necrosis Factors
• CPC Class Codes: C07K 16/468 Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention describes methods of treating erosive polyarthritis comprising administering a TNFα antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNFα antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.

Claims

1. A method of treatment of psoriasis in adult patients with moderate to severe active psoriatic arthritis (PsA), wherein each said patient has ≧

3 swollen and ≧

3 tender joints prior to the treatment and has failed NSAID therapy, comprising subcutaneously administering to each said patient 40 mg of adalimumab every other week, wherein 42% of said patients achieve 90% reduction in Psoriasis Area and Severity Index (PAST) score at week 24 of the treatment.

2. A method for treating moderate to severe chronic plaque psoriasis, comprising subcutaneously administering to an adult patient having moderate to severe chronic plaque psoriasis a first dose of 80 mg of adalimumab, followed by 40 mg of adalimumab every other week starting one week after said first dosing.

3. The method of claim 2, wherein adalimumab is comprised in pre-filled syringes for subcutaneous injection.

4. The method of claim 2, wherein the patient achieves at least a 75% reduction in PASI score at week 12 of the treatment.

5. The method of claim 4, wherein the patient achieves at least a 90% reduction in PASI score at week 12 of the treatment.

6. A method of preparing adalimumab for treatment of moderate to severe chronic plaque psoriasis, comprising filling adalimumab into syringes and subcutaneously administering adalimumab in the pre-filled syringes to an adult patient having moderate to severe chronic plaque psoriasis, wherein said subcutaneous administration includes a first dose of 80 mg of adalimumab, followed by 40 mg of adalimumab every other week starting one week after said first dosing.